We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Northw.Bio Regs | LSE:NWBS | London | Ordinary Share | COM SHS USD0.001 (REGS) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 13.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 13.00 | GBX |
Northw.Bio Regs (NWBS) Share Charts1 Year Northw.Bio Regs Chart |
|
1 Month Northw.Bio Regs Chart |
Intraday Northw.Bio Regs Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 17/7/2009 | 12:13 | Nationwide BS INCREASES mortgages 0.5%! 6 Aug 03 | 4 |
| 11/11/2008 | 10:32 | Northwest bio.di. | 149 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 16/7/2007 08:16 by gimme sunshine BOTHELL, Wash., July 16 /PRNewswire-FirstCalCertain media reports have erroneously stated that Company shareholders Toucan Capital and/or Toucan Partners have sold shares in the Company at the time of the PIPE financing in April 2006, at the time of the recent AIM financing, or at other times. Such reports are incorrect. Neither Toucan Capital nor Toucan Partners has sold shares in the Company, and, to the Company's knowledge, neither of them has such sales pending or planned. Moreover, as stated in the Company's Form 8-K filed on June 18, 2007, and the Company's AIM Admission Document dated June 18, 2007, each of Toucan Capital and Toucan Partners entered into a lock-up agreement with the respect to the shares of the Company's stock held by them, pursuant to which they agreed not to sell any shares held by them for twelve months following admission of the Company's shares to trading on AIM on June 22, 2007. Certain reports have also erroneously indicated that the Company has received a Marketing Authorization from the Swiss authorities. Such reports are incorrect. As previously announced, the Company applied to the Bundesamt fur Gesundheit ("BAG" or "Office Federal de la Sante Publique") for an Authorization for Use ("Autorisation d'exploitation"). NWBT has received such "Autorisation" from the BAG as an import/export authorization ("Autorisation pour activites transfrontalieres avec des transplants"). This authorization is conditional upon certain implementation commitments that NWBT will have to fulfill before the import/export activity can proceed (e.g., finalizing its pending arrangements for a clean-room suite for processing of patients' immune cells.) The process of this fulfillment is under way. The Authorization will allow the Company to export patients' immune cells and tumor tissue for vaccine manufacturing in the USA, and import the patients' DCVax(R)-Brain finished vaccine into Switzerland. In the BAG's processing and decision on the Company's "Autorisation" application and data, Swissmedic ("Institut Suisse des Agents Therapeutiques") only conducted the inspection and did not conduct any evaluation of the safety or efficacy of DCVax(R)-Brain. Such evaluation by Swissmedic will be done within the assessment of a Marketing Authorization Application. The Company plans to apply for Marketing Authorization by the end of this year. A Marketing Authorization is processed and decided by Swissmedic rather than the BAG, is not limited to selected centers, and allows full marketing and commercialization. About Northwest Biotherapeutics, Inc. Northwest Biotherapeutics, Inc. is a US-based biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. Disclaimer Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the company's ability to successfully commercialize DCVax(R)-Brain in Switzerland (including, without limitation, the regulatory, clinical and market aspects of such commercialization), the company's ability to enroll patients in its Phase II clinical trial of DCVax(R)-Brain and complete the trial on a timely basis, the uncertainty of the regulatory and clinical trials processes, the timely performance of third parties, and whether DCVax(R)-Brain will demonstrate safety and efficacy. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings and/or its AIM Admission Document and filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings and/or its AIM Admission Document and filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws. Northwest Biotherapeutics, Inc. |
Posted at 13/7/2007 18:17 by borchardt This is very frustrating - UK market makers reacted very positively to first day surge in US but London price is very poor compared to US now. Anyone know why there are 2 lines of stock in London? |
Posted at 12/7/2007 15:53 by andrbea the big-chip company dndn (prostate cancer vaccine)is having a bad week nwbo is the new kid on the bvlock! Dendreon Corp. shares fell in Thursday morning trading after an analyst downgraded the biotechnology company, saying a Securities and Exchange Commission investigation is just one of several pieces of bad news that will hurt the stock price. JMP Securities analyst Charles Duncan now rates the stock "Market Underperform," down from "Market Perform." He expects the stock to drop to $5 over the next year, down 37 percent from Wednesday's closing price. |
Posted at 11/7/2007 14:20 by andrbea interesting to see the latent effect of a new drug for prostrate cancer would have on a share pricecompare this story from March 2007 caused a 250% pre-market spike... |
Posted at 11/7/2007 08:57 by gimme sunshine I must admit that i do not know that much about Bio techs, but what stikes me is the fact that the swiss have given authority to use based on phase 11 clinical results.I would imagine that NWBS have also applied for the prostate treatment authority as well? that have been in P111 since early 06. I suppose the biggest concern when granting authority would be the concideration of the potential harm of the treatment. If the Technology is deemed safe then surely this will speed up the whole process for other applications, or is that silly? |
Posted at 10/7/2007 16:05 by andrbea While there has been tremendous hype and controversy surrounding companies developing cancer vaccines, including Dendreon (DNDN) and Cell Genesys (CEGE), a tiny Swiss biotech company took center stage on Monday. Northwest BioTherapeutics (NWBO.OB) announced that the Swiss Institute of Public Health had cleared its dendretic-cell vaccine, DCVax®-Brain, for commercial launch for treatment of brain cancerSo, it is possible that the company will produce the vaccine in the U.S., and end up selling it to Americans in Switzerland, at much higher prices! The company is currently conducting Phase II trials in both the U.S. and EU, but expects final results by end of 2008. The company is also cleared to investigate its DCVax® Technology platform in various other cancers, including a phase III trial for prostate cancer. This should make Dendreon investors a little nervous. The company's DCVax® Technology has tremendous advantages over competing cancer vaccine platforms. /.. Even following Monday's jump in share price, the company still has a tiny market cap of only $32 million. If you thought Dendreon shares are wild, think again! |
Posted at 10/7/2007 15:39 by andrbea In reaction, Collins Stewart reiterated its 'buy' recommendation and 300 pence target price on the stock and upped its 2008 forecasts for sales of 15 mln usd and a net profit of 3.3 mln usd |
Posted at 10/7/2007 13:57 by hi2eddie uk ticker nwbsus ticker nwbo |
Posted at 10/7/2007 13:56 by simonparker5 eddie it is ticker "NWBS". |
Posted at 10/7/2007 13:42 by hi2eddie US price $7.36 premaket trades going through |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
